The in vitro activities of cefinnoxime, cefotetan, and N-formimidoyl thienamycin were compared with those of other antimicrobial agents (metronidazole, clindamycin, cefoxitin, and moxalactam) against anaerobic bacteria. The data obtained indicate that N-fornimidoyl thienamycin exhibits excellent activity agaionst anaerobic bacteria; cefotetan and cefmenoxime, though less active, should be of value in teating selected anaerobic infections.
The rapidly increasing introduction of new 3- lactam antibiotics and the increasing recognition of the importance of anaerobic bacteria in infectious disease (2) has resulted in an ever-increasing need for information concerning the effectiveness of these antibiotics against anaerobic bacteria. The anaerobes have been shown to demonstrate various susceptibilities to currently available antibacterial agents (3) . Previous reports from this and other laboratories have demonstrated relatively poor activity of most newer P-lactam agents against anaerobic bacteria (1, 7, 8) . It f There is no implication intended that serum levels are important in the case of this organism. 8Clostridium perfringens, C. septicum, C. ramosum, C. subterminale, C. sporogenes, C. innocuum, C. sordellii, C. butyricum, C. clostridiiforme, and C. tertium.
h Eubacterium lentum, E. alactolyticum. Fusobacterium necrophorum, F. varium, F. naviforme. Peptococcus asaccharolyticus, P. magnus, P. prevotii, P. variabilis. k Peptostreptococcus anaerobius, P. micros. serum levels), with cefoxitin second best among the ,B-lactam drugs (inhibiting 92% at achievable serum levels). Clindamycin and moxalactam inhibited 94 and 85% of the strains, respectively, at achievable serum levels.
Of the drugs tested, metronidazole and Nformimidoyl thienamycin were the most active against the B. fragilis group, inhibiting 100% of the isolates at concentrations achievable in serum. Clindamycin and cefoxitin inhibited 98% of the B. fragilis group at such levels in this study. Both cefmenoxime and cefotetan showed relatively poor activity (46 and 53%, respectively) against members of the B. fragilis group at achievable serum levels. Serum levels achievable with cefotetan may prove to be higher (Table 1) . However, activity for these two drugs against non-B. fragilis group Bacteroides species was quite good, with cefmenoxime and cefotetan inhibiting 100 and 97% of the strains tested, respectively.
Metronidazole, N-formimidoyl thienamycin, and cefotetan were the most active compounds against Clostridium difficile strains. The poor activity of metronidazole against the non-sporeforming, gram-positive anaerobic bacilli has been previously reported by this and other laboratories (4, (8) (9) (10) and was confirmed in this study. 
